




RealRate

PHARMACEUTICAL 2023

ANI PHARMACEUTICALS INC Rank 221 of 446





RealRate

PHARMACEUTICAL 2023

ANI PHARMACEUTICALS INC Rank 221 of 446



The relative strengths and weaknesses of ANI PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ANI PHARMACEUTICALS INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 63% points. The greatest weakness of ANI PHARMACEUTICALS INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 97% points.

The company's Economic Capital Ratio, given in the ranking table, is 92%, being 49% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	344,261
Cost of Goods Sold	0
Intangible Assets	279,856
Liabilities, Current	99,439
Liabilities, Non-Current	287,050
Other Assets	92,724
Other Compr. Net Income	15,223
Other Expenses	190,537
Other Liabilities	35,058
Other Net Income	-27,382
Other Revenues	316,385
Property and Equipment	43,246
Research and Development	22,318
Selling, General and Administrative Expense	124,044

Output Variable	Value in 1000 USD
Assets	760,087
Liabilities	421,547
Expenses	336,899
Revenues	316,385
Stockholders Equity	338,540
Net Income	-47,896
Comprehensive Net Income	-40,284
Economic Capital Ratio	92%